When To Hold ’Em: Post-IPO, VCs Keep Their Cards

As biopharma IPOs show real signs of life, venture backers could reach exits they’ve been waiting on for years. Only a handful of investors with significant stakes have participated in multiple IPOs since the start of 2012.